Infomerics Valuation and Rating has upgraded the long-term bank facilities of Fredun Pharmaceuticals to IVR BBB+ with a stable outlook from IVR BBB with stable outlook while reaffirming the short-term rating at IVR A2.
Earlier, the company received a similar upgrade from Brickwork, raising its bank facility credit rating from A3+ to A2.
The bank facilities of the company work out to ₹156 crore.
The upgraded IVR BBB+ rating indicates an enhanced degree of safety regarding timely servicing of financial obligations and demonstrates improving credit quality. The stable outlook further signifies the rating agency’s confidence in the company’s ability to sustain its performance trajectory and maintain a balanced financial risk profile.
As Fredun Pharmaceuticals continues to expand its export presence across Africa, Southeast Asia, CIS countries and Latin America, the upgraded credit rating strengthens its financial flexibility to efficiently manage working capital and support strategic growth initiatives, the company said.
Fredun Medhora, Managing Director, said the rating reflects the hard work of employees and the disciplined manner in which the company is building the business.
“As we continue to grow across markets, our focus remains on strengthening the company’s foundation while pursuing larger opportunities responsibly,” he added.
Published on February 25, 2026